33.34 USD
-0.88
2.57%
Updated Dec 30, 12:01 PM EST
1 day
-2.57%
5 days
-1.94%
1 month
-27.27%
3 months
-32.55%
6 months
-41.30%
Year to date
-9.03%
1 year
-9.03%
5 years
108.38%
10 years
108.38%
 

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 374

0
Funds holding %
of 6,812 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,355% more call options, than puts

Call options by funds: $23.1M | Put options by funds: $1.59M

36% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 64

6.32% less ownership

Funds ownership: 92.3% [Q2] → 85.98% (-6.32%) [Q3]

7% less funds holding

Funds holding: 227 [Q2] → 211 (-16) [Q3]

22% less capital invested

Capital invested by funds: $2.16B [Q2] → $1.69B (-$478M) [Q3]

33% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 49

71% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 2 (-5) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$40
20%
upside
Avg. target
$52
54%
upside
High target
$72
116%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Stifel
Thomas Stephan
31% 1-year accuracy
5 / 16 met price target
20%upside
$40
Hold
Downgraded
20 Dec 2024
Wells Fargo
Larry Biegelsen
50% 1-year accuracy
23 / 46 met price target
26%upside
$42
Equal-Weight
Downgraded
11 Dec 2024
UBS
Danielle Antalffy
38% 1-year accuracy
5 / 13 met price target
56%upside
$52
Buy
Initiated
6 Dec 2024
Jefferies
Young Li
50% 1-year accuracy
1 / 2 met price target
116%upside
$72
Buy
Initiated
29 Oct 2024

Financial journalist opinion

Positive
Seeking Alpha
1 month ago
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, representing an 80% YoY increase in volume compared to the same period last year. The company's healthy balance sheet supports continued efforts in driving adoption within the U.S. market, while also maintaining the necessary R&D investments to remain innovative in the long run.
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Positive
Zacks Investment Research
1 month ago
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
RxSight (RXST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RxSight (RXST) Upgraded to Buy: Here's What You Should Know
Neutral
Seeking Alpha
1 month ago
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Conference Call Participants Lilia Lozada - J.P. Morgan Iseult McMahon - BTIG Lei Huang - Wells Fargo Craig Bijou - Bank of America Young Li - Jefferies Tom Stephan - Stifel Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Operator Thank you for standing by.
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.35 per share a year ago.
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3
Neutral
GlobeNewsWire
2 months ago
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
Neutral
GlobeNewsWire
4 months ago
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September.
RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
Positive
Seeking Alpha
4 months ago
Investing In The Future Of Cataract Surgery: The RxSight Advantage
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly expanding, with RxSight well-positioned to capitalize on the growing demand for premium IOLs. Impressive financial performance in Q2 2024, with significant revenue growth, gross profit margin improvement, and raised full-year revenue guidance.
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Positive
Zacks Investment Research
4 months ago
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
The mean of analysts' price targets for RxSight (RXST) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect?
Neutral
Seeking Alpha
4 months ago
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief Financial Officer Oliver Moravcevic - Vice President, Investor Relations Conference Call Participants Ryan Zimmerman - BTIG Robbie Marcus - J.P. Morgan Steven Lichtman - Oppenheimer & Co. Inc. David Saxon - Needham & Company Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Tom Stephan - Stifel Operator Good day and thank you for standing by.
RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
4 months ago
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
RxSight, Inc. (RXST) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.40 per share a year ago.
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
Charts implemented using Lightweight Charts™